Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02084160 · ClinicalTrials.gov registry record
Prediction Value of the BreathID 13C-Methacetin Breath Test for Hepatic Decompensation
A clinical trial, sponsored by Meridian Bioscience.
- Completed
- Registry status
- 579
- Enrollment target
NCT02084160 is a clinical trial that has completed, run by Meridian Bioscience. The registered enrollment target is 579 participants.
The verdict
NCT02084160 has completed, sponsored by Meridian Bioscience.
- COMPLETED
- Registry status
- 579 participants
- Enrollment target
Study Summary
The objectives of this study are: * To evaluate the ability of the Methacetin Breath Test (MBT) to detect hepatic decompensation events * To evaluate the relationship between liver Biopsy and clinical outcome and show that the MBT has a better predictive ability of clinical outcome than liver biopsy. * To evaluate the ability of the MBT to predict each of the individual liver related complications.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 579 participants |
| Start Date | 2014-03 |
| Est. Completion | 2018-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02084160
The ClinicalTrials.gov registry entry for NCT02084160 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 579 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Meridian Bioscience, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02084160 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02084160 about?
NCT02084160 is a clinical study titled "Prediction Value of the BreathID 13C-Methacetin Breath Test for Hepatic Decompensation". The objectives of this study are: * To evaluate the ability of the Methacetin Breath Test (MBT) to detect hepatic decompensation events * To evaluate the relationship between liver Biopsy and clinical outcome and show that the MBT has a better predictive ability of clinical outcome than liver biops...
What is the current status of trial NCT02084160?
This trial is currently completed. The enrollment target is 579 participants. The study started on 2014-03. Estimated completion is 2018-11.
Who is sponsoring clinical trial NCT02084160?
This trial is sponsored by Meridian Bioscience, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.